Youtube
AUROPHARMA

Aurobindo Pharma Ltd.

₹524.45

Score

29

Technically Bearish

Advice

Aurobindo Pharma Price Change Analysis

Aurobindo Pharma Key Statistics
  • P/E Ratio

    10.1

  • PEG Ratio

    -0.2

  • Market Cap Cr

    30729.5

  • Price to Book Ratio

    277.3

  • EPS

    53.1

  • Dividend

    400 ()

  • Relative Strength Index

    34.06

  • Money Flow Index

    34.6

  • MACD Signal

    -27.6

  • Average True Range

    25

Investment Ratings

  • Master Rating:

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Aurobindo Pharma Synopsis

NSE-Medical-Generic Drugs

Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 15823.68 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2021. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.
  • Market Cap

    30,624.10

  • Sales

    12,514.01

  • Shares in Float

    28.12

  • No of Funds

    612

  • Yield

    0.84

  • Book Value

    1.98

  • U/D Vol Ratio

    0.7

  • LTDebt/Equity

  • Alpha

    -0.27

  • Beta

    0.96

Aurobindo Pharma Ownership
Aurobindo Pharma Management

Aurobindo Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Aurobindo Pharma Financials

Aurobindo Pharma Technicals

EMA & SMA

CURRENT PRICE

EMA

Aurobindo Pharma Resistance and Support

Aurobindo Pharma Delivery and Volume

Aurobindo Pharma Price Change Analysis

Corporate Action

MF Shareholding

Similar Stocks

Videos

About Company

News

FAQs

Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

Aurobindo Pharma has an ROE of 24% which is exceptional.

Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

Aurobindo Pharma share price is

Open Demat Account